CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Pharming Group N.V. announced that CEO Sijmen de Vries will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, scheduled for September 12-14, 2022. De Vries will speak on September 13 at 09:30 ET (15:30 CET). Pharming focuses on developing innovative protein replacement therapies and precision medicines for rare diseases, with a global presence in over 30 markets. Interested parties can contact Pharming's Investor Relations for more information regarding the conference.

LEIDEN, The Netherlands, Sept. 7, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24^th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022. 

Pharming Group N.V.'s CEO will present on Tuesday, September 13 at 09:30 ET / 15:30 CET.

For more information about the conference, or to schedule a one-to-one with Pharming's management team, please contact your H.C. Wainwright representative, or send an email to Pharming's Investor Relations team to investor@pharming.com

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com or follow us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Heather Robertson, Investor Relations & Corporate Communications Manager
T: +31 71 5247 400
E: investor@pharming.com

FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw
T: +44 203 727 1000

FTI Consulting, USA
Jim Polson
T: +1 (312) 553-6730

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ceo-of-pharming-to-present-at-hc-wainwright-24th-annual-global-investment-conference-301618483.html

SOURCE Pharming Group N.V.

FAQ

When will the CEO of Pharming present at the H.C. Wainwright conference?

Sijmen de Vries, CEO of Pharming, will present on September 13, 2022, at 09:30 ET.

What is the location of the H.C. Wainwright Annual Global Investment Conference?

The conference will be held at the Lotte Palace Hotel in New York.

What is the purpose of the H.C. Wainwright conference for Pharming?

The conference provides an opportunity for Pharming's management to engage with investors and showcase the company's innovative therapies.

What type of therapies does Pharming Group develop?

Pharming develops protein replacement therapies and precision medicines for rare and debilitating diseases.

How can investors schedule a meeting with Pharming's management during the conference?

Investors can contact their H.C. Wainwright representative or email Pharming's Investor Relations team at investor@pharming.com.